Photocure: New Data on Cysview® to be presented at the upcoming AUA 2019 Annual Meeting
Oslo, Norway, April 8, 2019: Photocure ASA (PHO:OSE) announced today that Photocure will be exhibiting Blue Light Cystoscopy (BLC™) with Cysview in Booth 2214, during the American Urological Association Meeting (AUA 2019) in Chicago May 3rd-6th.
On the booth urologists will have the opportunity to experience BLC with Cysview, using both the rigid and flexible equipment.
BLC with Cysview will also be presented during plenary and poster sessions at the AUA annual meeting including:
May 3, 2019 (FRIDAY)
- 10:25 AM to 11:40 AM: Blue Light Cystoscopy for the diagnosis of Bladder Cancer by Dr. Badrinth Konety from University of Minnesota (Minneapolis, MN), MCP S105
- 4:45PM – 5:45 PM: Surgical Techniques: Tips & Tricks: Oncology Dr. Lotan, UTSW, (Dallas Tx) will present BLC with Cysview Flexible during the session W375e
May 4, 2019 (SATURDAY)
- 3:30 PM – 5:30 PM: Poster presentation: Flexible Blue Light Cystoscopy with Hexaminolevulinate provides opportunity to finalize Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer in the Outpatient Clinic. Results from a Nordic Registry Study, W181ab
About Bladder Cancer
Bladder cancer is the sixth most commonly diagnosed cancer in the US and is the fourth most common cancer found in men in the US.(1, 2) It is estimated that there will be 80,470 new cases of bladder cancer and 17,670 deaths due to bladder cancer in 2019.(3) Risk factors for bladder cancer include advancing age, cigarette smoking, occupational exposure to dyes, tar, rubber and solvent, and chronic bladder irritation and infections.(4) Bladder cancer is one of the most expensive cancers to manage. It is estimated that upwards of $5.71 billion will be spent on bladder cancer in the US in the year 2020.(5)
Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall.(4) NMIBC is in the inner layer of cells.(3) These cancers are the most common (75%) of all bladder cancer cases and include the subtypes carcinoma in situ (CIS), Ta and T1 lesions.(5) MIBC is when the cancer has grown into deeper layers of the bladder wall.(2) These cancers, including subtypes T2, T3 and T4, are more likely to spread and are harder to treat.(6)
About Hexvix®/Cysview® (hexaminolevulinate HCl)
Hexvix®/Cysview® is a drug that is selectively taken up by tumor cells in the bladder making them glow bright pink during Blue Light Cystoscopy (BLCTM). BLC™ with Hexvix® /Cysview® improves the detection of tumors and leads to more complete resection, fewer residual tumors and better management decisions.
Cysview® is the tradename in the US and Canada, Hexvix® is the tradename in all other markets. Photocure is commercializing Cysview® /Hexvix® directly in the US and the Nordic region and has strategic partnerships for the commercialization of Hexvix®/Cysview® in Europe, Canada, Australia and New Zealand. Please refer to https://bit.ly/2wzqSQQ for further information on our commercial partners.
All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.
For more information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Tel: + 1-609 759-6515
Email: ds@photocure.com
Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, which makes cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com
1 National Cancer Institute. SEER Stat Facts: Bladder Cancer 2017. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed on January 25, 2019.
2 American Cancer Society's (ACS) publication. Cancer Facts and Figures 2017: Special Section – Rare Cancers in Adults, and the ACS website. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf. Accessed on March 25, 2019.
3 American Cancer Society. Key Statistics for Bladder Cancer 2019. https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html. Accessed on March 25, 2019.
4 American Cancer Society. Bladder Cancer. http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-additional. Accessed on March 25, 2019.
5 Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2):117-28.
6 Pulver D, Schoenberg M, Pulver F. Bladder Cancer: A Patient-Friendly Guide to Understanding Your Diagnosis and Treatment Options. Patient-Friendly Publishing; 2017.